Dysentery
10
0
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
Efficacy of Rifaximin in Preventing Campylobacteriosis
Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
Social Network Interventions in Rural Honduras
Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections
Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations
New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management- Surveillance Study for Adverse Effects